Skin ConditionNCT05988567
Efficacy Testing of Melon Oil Olive Pressed Candy Products
A study testing melon and oil olive pressed candy in people with Skin Condition, run by TCI Co., Ltd. at 1 site in Taiwan.
Trial summary
To assess melon and oil olive pressed candy on skin condition improvement Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Skin Condition
- What is being tested?
- melon and oil olive pressed candy
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteTaiwan
- Study dates
- 9 May 2023to 31 Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy adults aged above 18 years old
- ITA° value 20°-41°
Who cannot join
- Involuntary subjects.
- Subjects who have a history of skin diseases such as psoriasis, eczema, atopic dermatitis, severe acne; or suffer from other chronic systemic disease.
- Those with known cosmetic, drug or food allergies.
- Female who is pregnant or nursing or planning to become pregnant during the course of the study.
- Subjects who have taken oral or topical corticosteroids and other anti-inflammatory drugs in the past 1 month.
- Use of any products or drugs that affect skin color such as fruit acid, salicylic acid (such as Hydroquinone preparations) in the past 2 months.
- In the past 3 months, the test site has used retinoic acid preparations or undergone chemical peeling, laser, pulse light and other medical aesthetic therapists
- Subjects who can not avoid long-term sun exposure
Trial locations and contacts
1 site in 1 country.
About this study
To assess melon and oil olive pressed candy on skin condition improvement
- Conditions
- Skin Condition
- Being tested
- Placebo candy, melon and oil olive pressed candy
- Medical subject headings
- Skin Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Placebo candyDietary supplement
consume 2 tablets per day
melon and oil olive pressed candyDietary supplement
Also called Melon, oil olive and pomegranate blend pressed candy
consume 2 tablets per day
| Study group | Role | What they receive |
|---|---|---|
| Placebo candy | Placebo comparator | Not described Receives: Dietary Supplement: Placebo candy |
| melon and oil olive pressed candy | Experimental | Not described Receives: Dietary Supplement: melon and oil olive pressed candy |
What is being measured
The primary outcome is the main question the study is designed to answer.
The change of skin wrinkles
VISIA Complexion Analysis System was utilized to measure skin wrinkles. Units: arbitrary units
Measured: Change from Baseline skin wrinkles at 12 weeks
The change of skin texture
VISIA Complexion Analysis System was utilized to measure skin texture. Units: arbitrary units
Measured: Change from Baseline skin texture at 12 weeks
The change of skin melanin index
Mexameter® MX18 was utilized to measure skin melanin index. Units: arbitrary units
Measured: Change from Baseline skin melanin index at 12 weeks
The change of skin erythema index
Mexameter® MX18 was utilized to measure skin erythema index. Units: arbitrary units
Measured: Change from Baseline skin erythema index at 12 weeks
The change of skin L* value
Chroma Meter MM500 was utilized to measure skin L* value. Units: arbitrary units
Measured: Change from Baseline L* value at 12 weeks
The change of skin b* value
Chroma Meter MM500 was utilized to measure skin b* value. Units: arbitrary units
Measured: Change from Baseline b* value at 12 weeks
The change of skin ITA° value
Chroma Meter MM500 was utilized to measure skin ITA° value. Units: arbitrary units
Measured: Change from Baseline ITA° value at 12 weeks
The change of skin spots
VISIA Complexion Analysis System was utilized to measure skin spots. Units: arbitrary units
Measured: Change from Baseline skin spots at 12 weeks
The change of skin UV spots
VISIA Complexion Analysis System was utilized to measure skin UV spots. Units: arbitrary units
Measured: Change from Baseline skin UV spots at 12 weeks
The change of skin brown spots
VISIA Complexion Analysis System was utilized to measure skin brown spots. Units: arbitrary units
Measured: Change from Baseline skin brown spots at 12 weeks
Secondary outcomes (3)
The change of TEAC of blood
Venous blood was sampled to measure TEAC
Measured: Change from Baseline TEAC at 12 weeks
The change of SOD of blood
Venous blood was sampled to measure SOD
Measured: Change from Baseline SOD at 12 weeks
The change of GSH-Px of blood
Venous blood was sampled to measure GSH-Px
Measured: Change from Baseline GSH-Px at 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2023
- Study start9 May 2023
- Primary completion1 Jun 2023
- Study completion31 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Skin ConditionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- TCI Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Chia-Hua Liang, Prof., Principal investigator, Chia Nan University of Pharmacy ＆ Science
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05988567
- Sponsor's protocol ID
- 23-049-B
- Status last verified
- Feb 2024
- First submitted
- 4 Aug 2023
- Last updated
- 21 Feb 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
He Y, Bu Y, Chiang CF, Lin YH, Liang CH, Chan LP, Sun J. Multi-Plant Concentrated Powder Improved Skin Whitening: A Double-Blinded, Randomized, and Placebo-Controlled Clinical Study. J Cosmet Dermatol. 2025 Feb;24(2):e70011. doi: 10.1111/jocd.70011.
PubMed 39927597
Study at a glance
From the registry record, last updated by the sponsor on 21 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy Testing of Melon Oil Olive Pressed Candy Products
- ClinicalTrials.gov ID
- NCT05988567
- Acronym / sponsor ID
- 23-049-B
- Conditions
- Skin Condition
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- TCI Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 9 May 2023 (actual)
- Primary completion
- 1 Jun 2023 (actual)
- Study completion
- 31 Dec 2023 (actual)
- First posted
- 14 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To assess melon and oil olive pressed candy on skin condition improvement
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo candy | Placebo comparator | Dietary Supplement: Placebo candy |
| melon and oil olive pressed candy | Experimental | Dietary Supplement: melon and oil olive pressed candy |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Healthy adults aged above 18 years old
- ITA° value 20°-41°
Key exclusion criteria (8 listed)
- Involuntary subjects.
- Subjects who have a history of skin diseases such as psoriasis, eczema, atopic dermatitis, severe acne; or suffer from other chronic systemic disease.
- Those with known cosmetic, drug or food allergies.
- Female who is pregnant or nursing or planning to become pregnant during the course of the study.
- Subjects who have taken oral or topical corticosteroids and other anti-inflammatory drugs in the past 1 month.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Placebo candyconsume 2 tablets per day | Dietary supplement | Placebo candy |
| melon and oil olive pressed candyAlso: Melon, oil olive and pomegranate blend pressed candyconsume 2 tablets per day | Dietary supplement | melon and oil olive pressed candy |
Primary outcome
The change of skin wrinkles
Time frame: Change from Baseline skin wrinkles at 12 weeks
VISIA Complexion Analysis System was utilized to measure skin wrinkles. Units: arbitrary units
The change of skin texture
Time frame: Change from Baseline skin texture at 12 weeks
VISIA Complexion Analysis System was utilized to measure skin texture. Units: arbitrary units
The change of skin melanin index
Time frame: Change from Baseline skin melanin index at 12 weeks
Mexameter® MX18 was utilized to measure skin melanin index. Units: arbitrary units
The change of skin erythema index
Time frame: Change from Baseline skin erythema index at 12 weeks
Mexameter® MX18 was utilized to measure skin erythema index. Units: arbitrary units
The change of skin L* value
Time frame: Change from Baseline L* value at 12 weeks
Chroma Meter MM500 was utilized to measure skin L* value. Units: arbitrary units
The change of skin b* value
Time frame: Change from Baseline b* value at 12 weeks
Chroma Meter MM500 was utilized to measure skin b* value. Units: arbitrary units
The change of skin ITA° value
Time frame: Change from Baseline ITA° value at 12 weeks
Chroma Meter MM500 was utilized to measure skin ITA° value. Units: arbitrary units
The change of skin spots
Time frame: Change from Baseline skin spots at 12 weeks
VISIA Complexion Analysis System was utilized to measure skin spots. Units: arbitrary units
The change of skin UV spots
Time frame: Change from Baseline skin UV spots at 12 weeks
VISIA Complexion Analysis System was utilized to measure skin UV spots. Units: arbitrary units
The change of skin brown spots
Time frame: Change from Baseline skin brown spots at 12 weeks
VISIA Complexion Analysis System was utilized to measure skin brown spots. Units: arbitrary units
3 secondary outcomes
The change of TEAC of blood
Time frame: Change from Baseline TEAC at 12 weeks
The change of SOD of blood
Time frame: Change from Baseline SOD at 12 weeks
The change of GSH-Px of blood
Time frame: Change from Baseline GSH-Px at 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Feb 2024.
- Derived from this study: PubMed 39927597He Y, Bu Y, Chiang CF, Lin YH, Liang CH, Chan LP, Sun J. Multi-Plant Concentrated Powder Improved Skin Whitening: A Double-Blinded, Randomized, and Placebo-Controlled Clinical Study. J Cosmet Dermatol. 2025 Feb;24(2):e70011. doi: 10.1111/jocd.70011.
Related trials for Skin Condition
Not yet recruitingPhase 2
Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)
Moderate to Severe Psoriatic Arthritis
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 1
IL-17 Blockade to Decrease irAEs (REPLAY)
Metastatic Melanoma
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chia-Hua Liang, Prof. principal investigator
Chia Nan University of Pharmacy ＆ Science
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing melon and oil olive pressed candy in people with Skin Condition, run by TCI Co., Ltd. at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The change of skin wrinkles (time frame: Change from Baseline skin wrinkles at 12 weeks). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05988567, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Feb 2024.